Dihydropyrimido fused ring derivative as HBV inhibitor

US9938301B2 · kind B2 · utility

Assignee

• QILU PHARMACEUTICAL CO., LTD. · CN

Inventors

• Haiying He · Shanghai, CN
• Kai ZHOU · Shanghai, CN
• Hua QIN · Shanghai, CN
• Xiaolin Li · San Diego, US
• Yuedong Zhou · Shanghai, CN
• Xiaofei Wang · Shanghai, CN
• Xuemei Chi · Shanghai, CN
• Jian Li · Shanghai, CN
• Shuhui CHEN · Shanghai, CN

Key dates

• Filing date: May 27, 2015
• Grant date: Apr 10, 2018
• Expiry date: May 27, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a dihydropyrimido fused ring derivative as a HBV inhibitor, and in particular relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof.